Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 59.3141
- Book/Share 20.4356
- PB 37.4926
- Debt/Equity 2.1838
- CurrentRatio 1.2777
- ROIC 0.277
- MktCap 686209105638.0
- FreeCF/Share -0.0559
- PFCF -13669.5041
- PE 49.6451
- Debt/Assets 0.3954
- DivYield 0.0076
- ROE 0.8836
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Berenberg | Buy | Hold | -- | $830 | Sept. 17, 2025 |
| Upgrade | LLY | HSBC Securities | Reduce | Hold | -- | $700 | Aug. 27, 2025 |
| Downgrade | LLY | Daiwa Securities | Outperform | Neutral | -- | $700 | Aug. 18, 2025 |
| Downgrade | LLY | Leerink Partners | Outperform | Market Perform | -- | $715 | Aug. 7, 2025 |
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial
Published: September 17, 2025 by: CNBC
Sentiment: Positive
Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. Eli Lilly said its pill, orforglipron, was superior at the trial's main goal of lowering blood sugar levels at 52 weeks compared to Novo Nordisk's oral semaglutide, and helped patients lose more weight.
Read More
Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial
Published: September 17, 2025 by: PRNewsWire
Sentiment: Neutral
For the primary endpoint, orforglipron lowered A1C by 2.2% vs. 1.4% with oral semaglutide at the highest doses Participants taking the highest dose of orforglipron lost an average of 19.7 lbs (9.2%) vs.
Read More
Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy
Published: September 17, 2025 by: Reuters
Sentiment: Positive
Eli Lilly has established itself as the market leader in obesity drugs in Europe, Asia and the Middle East and expects to replicate its U.S. dominance globally, the company's international president told Reuters on Wednesday.
Read More
Prospect of daily weight loss pill moves closer after Lily trial success
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
A once-a-day pill from Eli Lilly and Co (NYSE:LLY) has helped patients lose up to 20% of their body weight in trials, raising hopes of a more convenient alternative to injectable obesity drugs. The tablet, called orforglipron, works in the same way as blockbuster injections such as Wegovy and Mounjaro, targeting GLP-1 receptors to suppress appetite, slow digestion and improve blood sugar control.
Read More
Eli Lilly cautious on using FDA fast-track voucher for weight loss pill
Published: September 17, 2025 by: Reuters
Sentiment: Neutral
Eli Lilly's international president Patrik Jonsson said on Wednesday the company had little clarity on the U.S. Food and Drug Administration's new fast-track review process, cautioning it was too early to assume the firm would use it for its experimental weight-loss pill orforglipron.
Read More
GSK and Eli Lilly are the latest multinational drugmakers to unveil plans to build more U.S. manufacturing plants and other operations, moves aimed partly at mitigating the threat of tariffs
Published: September 16, 2025 by: WSJ
Sentiment: Positive
GSK and Eli Lilly are the latest to unveil plans to add to manufacturing and increase other operations in America.
Read More
Eli Lilly to invest $5B on Virginia plant amid Trump's pharma tariff threats
Published: September 16, 2025 by: Fox Business
Sentiment: Positive
Pharmaceutical giant Eli Lilly expanded its Virginia facility investment plans to $5 billion from original $2.1 billion amid the Trump administration tariff threats on drug imports.
Read More
"Reassessment" of LLY & NVO GLP-1 Projections Set New Guidance Tone
Published: September 16, 2025 by: Schwab Network
Sentiment: Positive
Lee Brown offers investor insight in the GLP-1 space in what he calls an industry with "expanding opportunity." He believes consumer sentiment has reset to proper expectations following sell-offs in Eli Lilly (LLY) and Novo Nordisk (NVO), anticipating significant upside following the repricing.
Read More
Eli lilly to invest $5 billion in new Virginia plant as pharma braces for tariffs
Published: September 16, 2025 by: Reuters
Sentiment: Positive
Eli Lilly said on Tuesday it will invest $5 billion to build a manufacturing facility in Virginia, the first of four new U.S. plants the drugmaker has planned as it moves to expand domestic production and hedge against potential tariffs.
Read More
Eli Lilly to build $5 billion Virginia facility to boost production of targeted cancer drugs, other treatments
Published: September 16, 2025 by: CNBC
Sentiment: Positive
Eli Lilly on Tuesday said it will spend $5 billion to build a manufacturing facility in Goochland County, Virginia, to boost production capacity for targeted cancer drugs and other treatments. The plant is the company's first of four planned U.S. manufacturing sites, which will begin making medicines within five years.
Read More
Lilly announces plans to build $5 billion manufacturing facility in Virginia
Published: September 16, 2025 by: PRNewsWire
Sentiment: Neutral
New site in Virginia's Goochland County will develop active pharmaceutical ingredients (API) in the U.S. for cancer, autoimmune and other advanced therapies Company will create 2,450 high-wage manufacturing and construction jobs This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year INDIANAPOLIS , Sept. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it plans to build a $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County.
Read More
Lilly Moves Past 50-Day SMA: Should You Consider Buying the Stock Now?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly shares move past the 50-day SMA as weight-loss drug data, rising sales and pipeline momentum fuel optimism.
Read More
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
Published: September 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug battleground
Published: September 12, 2025 by: CNBC
Sentiment: Neutral
Eli Lilly and Novo Nordisk are both preparing to launch obesity pills in the U.S. next year. Lilly expects results from a head-to-head trial of its pill orforglipron versus Novo's oral semaglutide in the coming months, said Lilly's Chief Scientific Officer Dan Skovronsky.
Read More
Lilly to participate in Bernstein's 2nd Annual Healthcare Forum
Published: September 11, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , Sept. 11, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025.
Read More
Novo Nordisk layoffs: 9,000 jobs cut as weight-loss drug competition with Eli Lilly heats up
Published: September 10, 2025 by: Fast Company
Sentiment: Negative
Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to encroach on its market share.
Read More
5 Large Drug Stocks to Watch Despite Industry & Macro Headwinds
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Negative
In the Large-Cap Pharmaceuticals industry, Lilly, J&J, Novartis, Pfizer and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
Eli Lilly (LLY) Just Reclaimed the 50-Day Moving Average
Published: September 10, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Eli Lilly (LLY) is looking like an interesting pick, as it just reached a key level of support. LLY recently overtook the 50-day moving average, and this suggests a short-term bullish trend.
Read More
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Sept 2025)
Published: September 10, 2025 by: 24/7 Wall Street
Sentiment: Positive
From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE: LLY) stock was on a tear, up more than 635%.
Read More
Our H2 2025 Top Ideas
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
The US economy is showing signs of slowing, with the labor market cooling, consumer sentiment weak, Q3 GDP expected to slow to ~1.3%, and inflation still above the Fed's 2% target. Stagflation is now becoming a real risk. Markets are expensive; the S&P 500 is near all-time highs, and broad-market ETFs like VOO, QQQ, and VTI may only deliver modest returns over the next few years.
Read More
LLY's Phase III Study on Jaypirca in Front-Line Leukemia Meets Goal
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly's Jaypirca shows a strong survival benefit over chemoimmunotherapy in treatment-naive CLL/SLL, boosting its potential in front-line use.
Read More
Will LLY's Oncology Portfolio Provide Key Diversification Benefits?
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's oncology portfolio, led by Verzenio and Jaypirca, is adding diversification to its cardiometabolic-driven growth story.
Read More
Eli Lilly launches AI platform for drug discovery
Published: September 09, 2025 by: Proactive Investors
Sentiment: Positive
Eli Lilly and Co (NYSE:LLY) has introduced Lilly TuneLab, an artificial intelligence and machine learning platform designed to support early-stage biotechnology companies in drug discovery. The system provides access to models trained on Lilly's proprietary datasets, which the company estimates represent more than $1 billion in research investment, the company said on Tuesday.
Read More
Eli Lilly And Company (LLY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 08, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Jacob Van Naarden - Executive VP & President of Lilly Oncology David Hyman - Chief Medical Officer Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Presentation Terence Flynn Equity Analyst Great. Thanks for joining us, everybody.
Read More
Eli Lilly And Company (LLY) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
Published: September 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) 2025 Wells Fargo Healthcare Conference September 5, 2025 9:30 AM EDT Company Participants Patrik Jonsson - Executive VP & President of Lilly International Mike Czapar - Director of Investor Relations Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Mohit Bansal Senior Equity Analyst Good morning. Thank you very much for being here on a Friday.
Read More
Is Eli Lilly Stock a Buy After Gaining 5% in 1 Day?
Published: September 05, 2025 by: The Motley Fool
Sentiment: Neutral
Eli Lilly (LLY 0.56%) is typically a market outperformer, but it has had a challenging year so far. Besides general market volatility, the company has dealt with clinical setbacks, lower-than-expected guidance, and the threat of tariffs.
Read More
Insider Watch: 3 CEOs Buying the Dip
Published: September 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors closely monitor insider buys, as they can give hints surrounding the long-term picture.
Read More
Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly
Published: September 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in thematic and leveraged exchange-traded funds, today announced the launch of the Defiance Daily Target 2X Short LLY ETF (Ticker: LLYZ).
Read More
These 3 Companies are Seeing Supercharged Sales Growth
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The 2025 Q2 earnings season is now behind us, with the period largely positive and resilient. Throughout the period, these three companies posted notably strong sales growth.
Read More
Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly's growing lineup beyond Mounjaro and Zepbound, including Omvoh and Jaypirca, is set to fuel revenue growth through 2025.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000